Gyre Therapeutics share price logo

Gyre Therapeutics

NASDAQ: GYRE

Small Cap

$6.09

+0.01

(+0.16%)

as on

Gyre Therapeutics Stock Performance

as on October 20, 2026 at 6:59 am IST

  • Day's Low

    Day's High

    $6.05
    $6.24
    downward going graph

    0.66%

    Downside

    2.46%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $5.44
    $9.14
    downward going graph

    10.67%

    Downside

    50.08%

    Upside

    downward going graph

Gyre Therapeutics share price movements today

Previous Close
$6.08
Open
$6.24
Volume
566.8K
Market Cap
$644.7M
Day's Low - High
$6.05 - $6.24
52 Week Low - High
$5.44 - $9.14

Gyre Therapeutics Historical Returns

1 Month Return
-19.47 %
3 Month Return
+ 0.5 %
1 Year Return
-26.75 %
3 Year Return
0 %
5 Year Return
0 %

Gyre Therapeutics Stock Fundamentals & Key Indicators

Check Gyre Therapeutics market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$644.7M

EPS (TTM)

-0.1989

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

1.66%

PE Ratio (TTM)

-30.57

Industry PE ratio

-7.03

PEG Ratio

0.34

EBITDA

-12.6M

Revenue (TTM)

119.4M

Profit Margin

94.30%

Return On Equity TTM

-15.77%

Gyre Therapeutics vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Gyre Therapeutics with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Gyre Therapeutics image
Gyre Therapeutics
Hold$644.7MNA-30.5794.30%0.00%
Moderna image
Moderna
Neutral$87.0B-34.65%-29.64-12.57%0.00%
Vertex Pharmaceuticals image
Vertex Pharmaceuticals
StrongBuy$126.7B169.53%28.8586.04%0.00%
Regeneron image
Regeneron
Buy$81.4B43.22%19.0184.86%0.47%

Stock Returns calculator for Gyre Therapeutics Stock including INR - Dollar returns

The Gyre Therapeutics stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

Gyre Therapeutics investment value today

Current value as on today

₹79,252

Returns

-₹20,748

(-20.75%)

Returns from Gyre Therapeutics Stock

-₹26,627 (-26.63%)

Dollar Impact

₹5,878 (+5.88%)

Analyst Recommendation on Gyre Therapeutics Stock

Based on 6 analysts

HOLD

0.00%

Buy

50.00%

Hold

50.00%

Sell

Based on 6 analysts, 50% of analysts recommend a 'HOLD' rating for Gyre Therapeutics. Average target price of $18.67

Gyre Therapeutics Share Price Target

Get share price movements and forecasts by analysts on Gyre Therapeutics.

What analysts predicted

67.38%UPSIDE

Target Price

$18.67

Current Price

$6.09

Analyzed by

6 Analysts

Target

$18.67

Gyre Therapeutics target price $18.67, a slight upside of 67.38% compared to current price of $6.09. According to 6 analysts rating.

Indian Investors' Interest in Gyre Therapeutics Stock

Search interest for Gyre Therapeutics Stock has increased by 10% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:10% versus previous 30 day period

Gyre Therapeutics Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
27
25
25
27
22
29
30
37
22
29
Gross Profit
26
24
24
26
21
28
28
35
21
26
Operating Income
8
3
4
0
2
-2
6
0
-9
-14
EBITDA
12
6
4
1
5
-1
8
0
-8
-12
Interest Expense
-
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
1
0
0
0
1
Income Before Tax
12
6
3
0
4
-1
7
0
-9
-14
Income Tax Expense
2
1
1
0
0
0
1
1
0
0
Net Income
7
3
1
0
2
0
3
-1
-8
-10
Net Profit Margin
96.40%
96.95%
96.24%
95.78%
95.95%
96.13%
94.67%
95.31%
94.55%
92.41%

Gyre Therapeutics Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Mar 2022
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
0
-
20
7
102
113
105
116
Gross Profit
0
0
0
11
0
97
108
101
111
Operating Income
-21
-33
-57
-57
-83
9
-67
16
11
EBITDA
-21
-33
-55
-56
-87
10
20
17
16
Interest Expense
-
-
-
-
-
-
-
-
-
Depreciation
0
0
0
0
0
1
1
1
2
Income Before Tax
-21
-30
-55
-56
-87
9
-76
23
14
Income Tax Expense
-
-
-
0
-
5
8
5
4
Net Income
-21
-30
-55
-55
-87
2
-92
12
5
Net Profit Margin
-1161.98%
-357800.00%
0.00%
56.26%
-4.52%
95.31%
95.91%
96.33%
95.35%

Gyre Therapeutics Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
9
3
1
0
3
1
5
-2
-8
-22
Operating Cash Flow
2
-5
1
-2
0
2
4
-5
3
-16
Investing Cash Flow
-7
-8
-2
-2
1
-3
-1
1
-3
9
Financing Cash Flow
0
0
0
0
1
22
0
0
0
0
Change in Cash
-3
-13
0
-4
3
21
3
-3
0
5

Gyre Therapeutics Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Mar 2022
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-21
-30
-55
-56
-87
4
-85
17
9
Operating Cash Flow
-19
-28
-43
-55
-83
10
25
-3
1
Investing Cash Flow
-11
-71
27
9
48
-13
-19
-19
0
Financing Cash Flow
35
111
0
60
49
-
2
2
24
Change in Cash
4
11
-15
14
13
-5
8
-21
25

Global Institutional Holdings in Gyre Therapeutics

Check out the Institutions with significant holdings in Gyre Therapeutics.

Funds
Holdings
Vanguard
1.46%
VANGUARD INDEX FUNDS
0.91%
iShares
0.51%
Fidelity Concord Street Trust
0.23%
Schwab
0.19%
See all

Insights on Gyre Therapeutics

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 2 quarters, 22.51M → 29.10M (in $), with an average increase of 22.6% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 738.2% return, outperforming this stock by 764.9%

  • imgNEGATIVE IMPACT

    Price Dip

    img

    In the last 7 days, GYRE stock has moved down by -11.4%

  • imgNEGATIVE IMPACT

    Profit Down

    img

    Netprofit is down for the last 4 quarters, 3.61M → -10.60M (in $), with an average decrease of 190.3% per quarter

About Gyre Therapeutics

Gyre Therapeutics, Inc. is a pharmaceutical company dedicated to discovering, advancing, and bringing to market small-molecule drugs that target inflammation and fibrosis in various organs. The company's key anti-fibrotic medication, ETUARY (Pirfenidone), has received approval for treating idiopathic pulmonary fibrosis. Beyond this, ETUARY is also undergoing late-stage (Phase 3) clinical trials for several other conditions, including dermatomyositis and interstitial lung disease linked to systemic sclerosis, pneumoconiosis, and diabetic kidney disease. The company's pipeline further includes F351 (Hydronidone), a compound structurally related to ETUARY. F351 is currently in Phase 3 studies for chronic hepatitis B-induced liver fibrosis and is in Phase 1 trials for liver fibrosis associated with nonalcoholic associated steatohepatitis (NASH). Other programs in development feature F573, which is progressing through Phase 2 studies for acute and acute-on-chronic liver failure. Additionally, two early-stage candidates, F528 and F230, are in preclinical development, focusing on chronic obstructive pulmonary disease (COPD) and pulmonary arterial hypertension (PAH), respectively. Established in 2002, Gyre Therapeutics, Inc. is based in San Diego, California, and operates as a subsidiary of GNI USA, Inc.
OrganisationGyre Therapeutics
Headquarters12770 High Bluff Drive, San Diego, CA, 92130, US
IndustryBiotechnology
CEOYing Luo

Key Management of Gyre Therapeutics

Name

Title

Mr. Thomas W. Eastling M.D.

Chief Financial Officer

Mr. Weiguo Ye

Chief Operating Officer

Dr. Ying Luo Ph.D.

CEO, President & Director

Dr. Yue Xiong Ph.D.

Chief Scientific Officer & Director

Mr. Joshua Bergmann J.D.

General Counsel & Corporate Secretary

Jing Liu Ph.D.

Senior Vice President of Platform Chemistry

Ms. Ruoyu Chen

Chief Information Officer

Seth Goldblum M.B.A.

Senior Vice President of Corporate Development

Mr. Jialiang Wang Ph.D.

Executive VP & GM

Mark Marino

Senior Vice President of Clinical Development

FAQs

What is Gyre Therapeutics share price today?

Gyre Therapeutics share price today is $6.09 as on at the close of the market. Gyre Therapeutics share today touched a day high of $6.24 and a low of $6.05.

What is the 52 week high and 52 week low for Gyre Therapeutics share?

Gyre Therapeutics share touched a 52 week high of $9.14 on and a 52 week low of $5.44 on . Gyre Therapeutics stock price today i.e. is closed at $6.09,which is 33.37% down from its 52 week high and 11.95% up from its 52 week low.

What is Gyre Therapeutics's market capitalisation today?

Gyre Therapeutics market capitalisation is $0.00T as on .

How to invest in Gyre Therapeutics Stock (GYRE) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Gyre Therapeutics on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Gyre Therapeutics Stock (GYRE) from India?

Indian investors can start investing in Gyre Therapeutics (GYRE) shares with as little as ₹94.91500091552734 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹949.15 in Gyre Therapeutics stock (as per the Rupee-Dollar exchange rate as on ). Based on Gyre Therapeutics share’s latest price of $6.09 as on October 20, 2026 at 1:29 am IST, you will get 1.6420 shares of Gyre Therapeutics. Learn more about fractional shares .